|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: new biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sánchez de Cos J, Sojo González MA,
Montero MV, Pérez Calvo MC, Vicente MJ and Valle MH: Non-small cell
lung cancer and silent brain metastasis. Survival and prognostic
factors. Lung Cancer. 63:140–145. 2009. View Article : Google Scholar
|
|
4
|
Osman A: MicroRNAs in health and
disease-basic science and clinical applications. Clin Lab.
58:393–402. 2012.
|
|
5
|
Mendell JT and Olson EN: microRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wen J, Li R, Wen X, Chou G, Lu J, Wang X
and Jin Y: Dysregulation of cell cycle related genes and microRNAs
distinguish the low- from high-risk of prostate cancer. Diagn
Pathol. 9:1562014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen PS, Su JL and Hung MC: Dysregulation
of microRNAs in cancer. J Biomed Sci. 19:902012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Melo SA and Esteller M: Dysregulation of
microRNAs in cancer: playing with fire. FEBS Lett. 585:2087–2099.
2011. View Article : Google Scholar
|
|
9
|
Bartel DP: microRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boeri M, Pastorino U and Sozzi G: Role of
microRNAs in lung cancer: microRNA signatures in cancer prognosis.
Cancer J. 18:268–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guz M, Rivero-Müller A, Okoń E,
Stenzel-Bembenek A, Polberg K, Słomka M and Stepulak A: microRNAs -
role in lung cancer. Dis Markers. 2014:2181692014. View Article : Google Scholar
|
|
12
|
Lin SP, Youngson N, Takada S, Seitz H,
Reik W, Paulsen M, Cavaille J and Ferguson-Smith AC: Asymmetric
regulation of imprinting on the maternal and paternal chromosomes
at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat
Genet. 35:97–102. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Peng B, Wang D, Ma X, Jiang D,
Zhao J and Yu L: Human tumor microRNA signatures derived from
large-scale oligonucleotide microarray datasets. Int J Cancer.
129:1624–1634. 2011. View Article : Google Scholar
|
|
14
|
Miranda PJ, Vimalraj S and Selvamurugan N:
A feedback expression of microRNA-590 and activating transcription
factor-3 in human breast cancer cells. Int J Biol Macromol.
72:145–150. 2015. View Article : Google Scholar
|
|
15
|
Xin C, Zhang H and Liu Z: miR-154
suppresses colorectal cancer cell growth and motility by targeting
TLR2. Mol Cell Biochem. 387:271–277. 2014. View Article : Google Scholar
|
|
16
|
Mian C, Pennelli G, Fassan M, Balistreri
M, Barollo S, Cavedon E, Galuppini F, Pizzi M, Vianello F, Pelizzo
MR, et al: microRNA profiles in familial and sporadic medullary
thyroid carcinoma: preliminary relationships with RET status and
outcome. Thyroid. 22:890–896. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai
H, Li P, Cao Q, Ju X, Meng X, et al: miR-154 inhibits EMT by
targeting HMGA2 in prostate cancer cells. Mol Cell Biochem.
379:69–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu C, Shao P, Bao M, Li P, Zhou H, Cai H,
Cao Q, Tao L, Meng X, Ju X, et al: miR-154 inhibits prostate cancer
cell proliferation by targeting CCND2. Urol Oncol.
32:31.e39–31.e16. 2014. View Article : Google Scholar
|
|
19
|
Huang J, Wu J, Li Y, Li X, Yang T, Yang Q
and Jiang Y: Deregulation of serum microRNA expression is
associated with cigarette smoking and lung cancer. Biomed Res Int.
2014:3643162014.PubMed/NCBI
|
|
20
|
Soerjomataram I, Lortet-Tieulent J, Parkin
DM, Ferlay J, Mathers C, Forman D and Bray F: Global burden of
cancer in 2008: a systematic analysis of disability-adjusted
life-years in 12 world regions. Lancet. 380:1840–1850. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen WQ, Zheng RS, Zhang SW, Zeng HM and
Zou XN: The incidences and mortalities of major cancers in China,
2010. Chin J Cancer. 33:402–405. 2014.PubMed/NCBI
|
|
22
|
Gururajan M, Josson S, Chu GC, Lu CL, Lu
YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, et al: miR-154*
and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate
epithelial to mesenchymal transition and bone metastasis of
prostate cancer. Clin Cancer Res. 20:6559–6569. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S,
Chen Y and Wu K: Notch signaling and EMT in non-small cell lung
cancer: biological significance and therapeutic application. J
Hematol Oncol. 7:872014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang JH, Liu C, Cheng H, Lu Y, Qin Y, Xu
YF, Xu J, Long J, Liu L, Ni QX, et al: Epithelial-mesenchymal
transition in pancreatic cancer: is it a clinically significant
factor? Biochim Biophys Acta. 1855:43–49. 2015.
|
|
25
|
Zheng H and Kang Y: Multilayer control of
the EMT master regulators. Oncogene. 33:1755–1763. 2014. View Article : Google Scholar
|
|
26
|
Mateen S, Raina K, Agarwal C, Chan D and
Agarwal R: Silibinin synergizes with histone deacetylase and DNA
methyltransferase inhibitors in upregulating E-cadherin expression
together with inhibition of migration and invasion of human
non-small cell lung cancer cells. J Pharmacol Exp Ther.
345:206–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Liu G, Kang Y, Dong Z, Qian Q and
Ma X: N-cadherin expression is associated with acquisition of EMT
phenotype and with enhanced invasion in erlotinib-resistant lung
cancer cell lines. PLoS One. 8:e576922013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brennecke J, Stark A, Russell RB and Cohen
SM: Principles of microRNA-target recognition. PLoS Biol.
3:e852005. View Article : Google Scholar : PubMed/NCBI
|
